2022
MINIAS
Acquisition of Bayer’s Lormetazepam product portfolio in Italy and Japan (March)
2021
MODURETIC AND ANTROLIN
Commercial agreement with MSD for the right to commercialize Moduretic (February).
Acquisition of the global full rights to commercialize Antrolin, previously soldi in Italy through a license agreement (April)
2019
MDM ACQUISITION
Neopharmed acquires MDM, a pharmaceutical company active in neurology and orthopedics
2018
ARDIAN ENTRY
Ardian acquires a majority stake in Neopharmed. Del Bono family retains a minority stake Alessandro Del Bono remains as CEO
2017
THERABEL ACQUISITION
Acquisition of the products of Therabel‘s Italian branch
2017
TEVA’S PARTNERSHIP
Neopharmed signs a partnership with Teva for the promotion and development of 3 patended respiratory products in the Italian market
2011
NEOPHARMED GENTILI
Istituto Gentili and Neopharmed are merged to form Neopharmed Gentili
2009
FIRST ACQUISITION
Under Alessandro Del Bono‘s leadership, Mediolanum acquires Istituto Gentili (Merck’s ltalian branch focused on orthopedics and on respiratory) and Neopharmed (Merck’s ltalian branch focused on cardio)
1972
MEDIOLANUM FARMACEUTICI
Mediolanum Farmaceutici, focused on primary care drugs, is founded in Milan
